Eupraxia Pharmaceuticals presented data from its Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE) at Digestive Disease Week in Chicago. The trial showed a dose-response relationship between the number of injections and improvements in disease markers, supporting selection of a full 20-injection protocol for the placebo-controlled Phase 2b portion.
Study Design and Measurements
The RESOLVE trial evaluated EP-104GI via 4 to 20 esophageal wall injections, with patients followed for up to 24 weeks in early cohorts or 52 weeks in later ones. Researchers used the EREFS scoring system, a validated visual measure of five endoscopic features of EoE: edema, rings, exudates, furrows, and strictures. Individuals without EoE typically have EREFS at or near zero; patients with active EoE tend to present scores above 2. Achieving an EREFS below 2 points has been validated as a response threshold.
Key Findings
Of 30 total participants, 25 (83%) presented with baseline EREFS scores above 2. For patients receiving 20 injections (resulting in near full esophageal coverage), the mean EREFS reduction was 65% (3.6 points) from baseline at week 12 (n=7). In the highest-dose cohorts (20x6mg and 20x8mg, combined n=4), EREFS improvement was near complete. EoEHSS inflammatory and fibrosis sub-scores also indicated that higher-dose cohorts showed potentially greater improvement.
The Phase 2b portion of the RESOLVE trial, currently recruiting both the 120mg and 160mg doses, is expected to deliver top-line data in Q4 2026. EoE affects more than 450,000 people in the United States and has been identified as rapidly increasing in both incidence and prevalence by the American Gastroenterological Association.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.globenewswire.com/news-release/2026/05/05/3287509/0/en/Eupraxia-Pharmaceuticals-Reports-EREFS-Data-from-its-Ongoing-Phase-1b-2a-RESOLVE-Trial-in-Eosinophilic-Esophagitis-at-Digestive-Disease-Week-DDW.html